Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04721132 · ClinicalTrials.gov registry record · Phase 2

Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer

A Phase 2 study of Resectable Hepatocellular Carcinoma and Stage IB Hepatocellular Carcinoma AJCC v8, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
16
Enrollment target
2
Study locations

NCT04721132 is a Phase 2 study of Resectable Hepatocellular Carcinoma and Stage IB Hepatocellular Carcinoma AJCC v8 that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 16 participants, below the 47-participant average among 4 other Resectable Hepatocellular Carcinoma trials with a reported enrollment target (66% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04721132, a Phase 2 study of Resectable Hepatocellular Carcinoma and Stage IB Hepatocellular Carcinoma AJCC v8, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
16 participants
Enrollment target
2
Study locations

Study Summary

This phase II trial studies the effect of atezolizumab and bevacizumab before surgery in treating patients with liver cancer that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving the combination of atezolizumab and bevacizumab may help to prevent liver cancer from returning after surgery.

Conditions Studied

Resectable Hepatocellular Carcinoma Stage IB Hepatocellular Carcinoma AJCC v8 Stage II Hepatocellular Carcinoma AJCC v8 Stage I Hepatocellular Carcinoma AJCC v8 Stage IA Hepatocellular Carcinoma AJCC v8

Interventions

  • BIOLOGICAL Atezolizumab
  • PROCEDURE Therapeutic Conventional Surgery
  • BIOLOGICAL Bevacizumab

Study Locations (2)

Texas

  • Houston Methodist Hospital - Houston
  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2021-02-10
Est. Completion 2027-12-31
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04721132

The ClinicalTrials.gov registry entry for NCT04721132 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 47-participant average among 4 other Resectable Hepatocellular Carcinoma trials with a reported enrollment target (66% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Resectable Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.

NCT04721132 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04721132 about?

NCT04721132 is a clinical study titled "Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer". This phase II trial studies the effect of atezolizumab and bevacizumab before surgery in treating patients with liver cancer that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may inter...

What is the current status of trial NCT04721132?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2021-02-10. Estimated completion is 2027-12-31.

What conditions does trial NCT04721132 study?

This clinical trial studies the following conditions: Resectable Hepatocellular Carcinoma, Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8.

What interventions are being tested in trial NCT04721132?

The interventions under investigation include: Atezolizumab (BIOLOGICAL), Therapeutic Conventional Surgery (PROCEDURE), Bevacizumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT04721132?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04721132 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Resectable Hepatocellular Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Resectable Hepatocellular Carcinoma

All registered trials for this condition

Stage IB Hepatocellular Carcinoma AJCC v8

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.